contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


genovis-receives-order-worth-approximately-1-million-euros-from-global-pharmaceutical-company

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Genovis är verksamt inom bioteknik. Störst inriktning återfinns mot utveckling av enzymer som används i diverse läkemedel. Bolagets patenterade NIMT teknologi är utvecklad för att underlätta för LifeScience industrin att bedriva preklinisk forskning. Bolagets produkter vidaresäljs under ett flertal varumärken. Genovis etablerades 1999 och har sitt huvudkontor i Lund.

Genovis

Genovis AB, a leading provider of innovative enzyme technologies, today announced it has received an order with a total value of approximately EUR 1 million (SEK 11 million) from a global pharmaceutic...

<div class="mfn-preamble"><p><strong>Genovis AB, a leading provider of innovative enzyme technologies, today announced it has received an order with a total value of approximately EUR 1 million (SEK 11 million) from a global pharmaceutical company. The order includes material and related services connected to one of Genovis’ proprietary antibody conjugation technology platforms.</strong></p></div><div class="mfn-body"><p>Genovis’ technology platform will be used as part of the manufacturing process to produce material for a novel drug candidate currently in preclinical development, and is expected to remain part of the manufacturing process if the program progresses into clinical development. Manufacturing of the reagents required to support the project will begin immediately, and delivery is expected to be completed no later than early 2026.</p><p>“We are proud to support this important program and pleased that our technology platforms continue to enable the development of innovative biopharmaceuticals,” says Fredrik Olsson, CEO of Genovis.</p><p>This order represents a significant milestone for Genovis’ bioconjugation business and highlights the growing importance of the company’s technologies in the field of next-generation therapeutics.</p></div><div class="mfn-footer mfn-contacts mfn-14e334f030f1"><p><strong class="mfn-heading-1">Contacts</strong><br>Fredrik Olsson, CEO <br>Tel: +46 (0)70-276 46 56&nbsp;<a rel="noopener" href="mailto:fredrik.olsson@genovis.com">fredrik.olsson@genovis.com</a></p></div><div class="mfn-footer mfn-about mfn-fac8387f094b"><p><strong class="mfn-heading-1">About Us</strong><br>Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis enzyme products, known as SmartEnzymes, are used by scientists all over the world and the innovative product formats facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and DNB Carnegie Investment Bank AB is the Company’s Certified Adviser.</p><p><em>This is a translation of the Swedish original. In the event of&nbsp;any discrepancy&nbsp;between this translation and the&nbsp;Swedish original, the&nbsp;Swedish&nbsp;version&nbsp;shall prevail.</em></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Genovis is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-17 08:30 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a0f92967-39ec-4b51-9e59-46d1364a7d8c/genovis-receives-order-worth-approximately-1-million-euros-from-global-pharmaceutical-company.pdf" class="mfn-generated mfn-primary">Genovis receives order worth approximately 1 million euros from global pharmaceutical company</a></p></div>

Genovis receives order worth approximately 1 million euros from global pharmaceutical company